Tag
5 articles tagged Drug Discovery.
Chai Discovery is positioning AI protein design as a neutral software factory for pharma partners. The company has partnered with Eli Lilly, Pfizer, Novartis, and Argenx to accelerate antibody and binder discovery. Its visual design suite, compute infrastructure, and partner specific fine tuning create a platform model for precision drug engineering.
An exploration of how Noetic is leveraging multimodal foundation models to solve the patient selection problem in cancer drug development, moving away from traditional cell lines toward patient-centric data moats.
OpenAI leaders discuss the deployment of specialized biochemistry models for life sciences. The analysis covers the shift from human to compute bottlenecks, the strategic implementation of differentiated access for biosecurity, and the integration of agentic workflows into wet-lab automation.
DeepMind CEO Demis Hassabis discusses the five-year window for AGI, the shift from scaling laws to algorithmic innovation, and the potential for AI to solve global energy and health crises.
Andrew White of Edison Scientific discusses the shift from first-principles simulation to LLM-driven scientific automation. The analysis covers the 'world model' architecture, the limitations of human scientific taste, and the strategic pivot from academic research to venture-backed AI labs.
